135 Real World Experience with Use of Coagulation Factor VIIa (Recombinant)-jncw (SevenFact®) at an Academic Medical Center

Introduction: Eptacog beta (SevenFact®) is a recombinant factor VIIa (rVIIa) analog newly approved by the Food and Drug Administration for the prevention and treatment of bleeding in those aged 12 years or older with hemophilia A or B with inhibitors. In July 2023, our institution converted from eptacog alfa (NovoSeven®) to eptacog beta for all indications except congenital factor VII deficiency, for which eptacog beta is not recommended. The objective was to evaluate rVIIa prescribing and clinical outcomes after a formulary interchange.